Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

about

Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes

P2860

Q58762847-40B2BAE9-8654-43D9-ADC7-A60601AA20C9 Q59133785-F211535C-3762-42C7-AE0D-022C38BE61F9

P2860

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

Item

http://www.wikidata.org/entity/Q37616489

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

@en

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

@nl

type

Item

label

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

@en

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

@nl

prefLabel

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

@en

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

@nl

P1476

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles

@en

P2093

Christina Pham

http://www.w3.org/2001/XMLSchema#string

Duane A Mitchell

http://www.w3.org/2001/XMLSchema#string

Elias J Sayour

http://www.w3.org/2001/XMLSchema#string

Gabriel De Leon

http://www.w3.org/2001/XMLSchema#string

Hanna Kemeny

http://www.w3.org/2001/XMLSchema#string

Jianping Huang

http://www.w3.org/2001/XMLSchema#string

Joshua Chua

http://www.w3.org/2001/XMLSchema#string

Luis Sanchez-Perez

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics

Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects

Cancer nanotechnology: opportunities and challenges

Nanocarriers as an emerging platform for cancer therapy

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.

Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

P304

e1256527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2016.1256527

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

J H Sampson

Catherine Flores

Adam Grippin

P577

2016-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28197373

http://www.w3.org/2001/XMLSchema#string

P932

5283636

http://www.w3.org/2001/XMLSchema#string

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

about

P2860

P2860

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932